Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer-Reference-Cited by-同舟云学术

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

Published:2008-02 Issue:2 Volume:19 Page:340-347
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Boeck S.,Hoehler T.,Seipelt G.,Mahlberg R.,Wein A.,Hochhaus A.,Boeck H.-P.,Schmid B.,Kettner E.,Stauch M.,Lordick F.,Ko Y.,Geissler M.,Schoppmeyer K.,Kojouharoff G.,Golf A.,Neugebauer S.,Heinemann V.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/2/340/723939/mdm467.pdf

Reference24 articles.

1. Clinical cancer advanced 2006: major research advanced in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology;Ozols;J Clin Oncol,2007

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

3. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials;Heinemann;Semin Oncol,2002

4. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer;Hochster;Cancer,2006

5. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer;Heinemann;J Clin Oncol,2006

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group;ESMO Open;2024-04

2. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?;Clinical and Translational Oncology;2023-10-04

3. Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade;Pharmacological Research;2022-07

4. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis;Annals of Palliative Medicine;2020-07

5. Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer;Cancers;2019-11-07